Close Menu

NEW YORK (GenomeWeb) – Wells Fargo's Equity Research Department today downgraded Foundation Medicine's stock to Market Perform from Outperform, following the company's first ever analyst day on Tuesday.

Wells Fargo also increased its 2016 estimated loss per share for Foundation Medicine to $1.36 from $1.29, and reduced its stock valuation range to $25 to $27 per share from a previous $35 to $40 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.